Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
Category: News
The model could lead to more targeted treatments for the disease
An estimated 7.5 million people will be invited to receive the booster
AI-powered SkyMind is designed to improve efficiency, compliance and decision-making
Approximately 55,100 new cases of prostate cancer are diagnosed every year in the UK
Research targets lysosomal function restoration for neurodegeneration
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) […]
Approval extends ustekinumab’s use to younger patients
Collaboration introduces automation to enhance efficiency
GMP certification enables 4basebio to supply DNA for clinical trials